DNA-testing site 23andMe fights for survival

The 23andMe logo at the company headquarters in California
[Getty Images]

Three years ago, the DNA-testing firm 23andMe was a massive success, with a share price higher than Apple's.

But, from those heady days of millions of people rushing to send it saliva samples in return for detailed reports about their ancestry, family connections and genetic make-up, it now finds itself fighting for its survival.

Its share price has plummeted and this week it narrowly avoided being delisted from the stock market.

And of course this is a company that holds the most sensitive data imaginable about its customers, raising troubling questions about what might happen to its huge – and extremely valuable – database of individual human DNA.

When contacted by the BBC, 23andMe was bullish about its prospects - and insistent it remained "committed to protecting customer data and consistently focused on maintaining the privacy of our customers."

But how did what was once one of the most talked-about tech firms get to the position where it has to answer questions about its very survival?

DNA gold rush

Not so long ago, 23andMe was in the public eye for all the right reasons.

Its famous customers included Snoop Dogg, Oprah Winfrey, Eva Longoria and Warren Buffett - and millions of users were getting unexpected and life-changing results.

Some people discovered that their parents were not who they thought they were, or that they had a genetic pre-disposition to serious health conditions. Its share price rocketed to $321.

Fast forward three years and that price has slumped to just under $5 - and the company is worth 2% of what it once was.

What went wrong?

Co-founder Anne Wojcicki with then husband Sergei Brin at a 23andMe so-called "Spit party" in New York
Co-founder Anne Wojcicki with then husband Sergei Brin at a 23andMe "Spit party" in New York [Getty Images]

According to Professor Dimitris Andriosopoulos, founder of the Responsible Business Unit at Strathclyde University, the problem for 23andMe was twofold.

Firstly, it didn’t really have a continuing business model – once you’d paid for your DNA report, there was very little for you to return for.

Secondly, plans to use an anonymised version of the gathered DNA database for drug research took too long to become profitable, because the drug development process takes so many years.

That leads him to a blunt conclusion: “If I had a crystal ball, I’d say they will maybe last for a bit longer,” he told the BBC.

“But as it currently is, in my view, 23andMe is highly unlikely to survive.”

The problems at 23andMe are reflected in the turmoil in its leadership.

The board resigned in the summer and only the CEO and co-founder Anne Wojcicki – sister of the late YouTube boss Susan Wojcicki and ex-wife of Google co-founder Sergei Brin – remains from the original line-up.

Rumours have swirled that the firm will shortly either fold or be sold - claims that it rejects.